Feline – Chronic Rhinitis

Snorting and Sneezing Cats: Managing Chronic Snufflers  ABVP 2011

Susan Little, DVM, DABVP (Feline Practice)

This text has been modifies for in-house client informational purposes by Dr. Kate Lucas

One of the most common and frustrating syndromes causing sneezing and nasal discharge in cats is chronic rhinosinusitis ('chronic snufflers'). While chronic rhinosinusitis (CRS) is commonly associated with viral infection, many affected cats have no history of viral infection or other predisposing causes. A complete diagnostic workup is important to identify the underlying etiology when possible.

Unfortunately, for most cats, a cure is not possible and treatment is often life-long.

Clinical Signs

Cats with CRS are typically presented for sneezing and noisy breathing. Nasal discharge may be clear or mucous or even pus, if secondary bacterial infection occurs, and is usually bilateral. Unilateral nasal discharge is more likely to be associated with a foreign body or cancer. Clear discharge is most likely associated with viral or allergic etiologies. Sanguineous discharge may be associated with intermittent hemorrhage due to inflammation. Occasionally, affected cats are lethargic and anorectic, but generally they are otherwise well. Other clinical signs include ocular discharge, squinting, trouble swallowing and halitosis. Clinical signs often persist for years, and in some cases, they are seasonal, suggesting an allergic component.

Etiology/Causes

Some, but not all, cats with CRS have a history of infection with feline herpesvirus (FHV-1) or feline calicivirus (FCV) at a young age. Early severe viral infection, particularly with FHV-1, may trigger chronic disease2 although the role of FHV-1 in CRS remains unclear. In one study of 10 cats with CRS and 7 normal cats, FHV-1 was not found on virus isolation, but was detected by PCR in both groups of cats, indicating actively replicating virus was not present. One theory is that FHV-1 is the inciting cause of CRS, but active infection is not present in symptomatic cats. FHV-1 infection of the respiratory epithelium causes areas of multifocal epithelial necrosis as well as bony changes in the turbinate bones that may be permanent. The damaged nasal bones seem to be prone to secondary bacterial infections, possibly because loss of normal nasal architecture disrupts mucociliary function and results in trapping of mucus and bacteria. Latency occurs in approximately 80% of cats infected with FHV-1 and recrudescence may be triggered by stressful events, such as crowding in multi-cat environments, re-homing, immunosuppressive drug therapy, concurrent diseases, etc.

Many affected cats improve when treated with broad spectrum antibiotics but relapse once therapy is discontinued, implying that bacterial infection plays at least a contributory role in CRS. Both aerobic and
anaerobic bacterial species can be cultured from biopsy samples and nasal flush samples from cats with CRS. Primary causes of upper respiratory tract disease in cats are uncommon, and include Bordetella bronchiseptica, Mycoplasma spp., Streptococcus canis, and Chlamydophila felis. A recent study failed to link Bartonella spp. to CRS in cats. The normal bacterial flora of the feline nasal cavity includes Pasteurella, Staphylococcus and Streptococcus, as well as anaerobic bacteria.

**Diagnosis**

Diagnosis is often one of exclusion, after ruling out other etiologies, such as trauma, neoplasia (especially lymphoma), fungal infection (e.g., Cryptococcus), periodontal disease, nasal foreign body, and nasopharyngeal polyps. A careful physical examination and medical history are very important for the diagnosis of CRS. The face, especially the nose, should be examined carefully for deformity, pain or swelling. The oral cavity should be evaluated for periodontal disease, especially tooth root abscesses.

A minimum database should be collected (complete blood cell count, serum chemistry panel, urinalysis, FeLV/FIV testing). Fungal serology may be appropriate in certain geographic areas. Cats with recurrent signs may require further diagnostic testing, such as rhinoscopy and skull radiography. Biopsies should be obtained during rhinoscopy even if the mucosa appears normal. The caudal nasopharyngeal cavity can also be examined under sedation with the use of a dental mirror and a spay hook to retract the soft palate. Histopathologically, affected cats are categorized as having lymphocytic-plasmacytic, eosinophilic, or idiopathic rhinosinusitis. Nasal flushing is sometimes useful to remove mucus, although the benefits are short lived. Nasal flush samples can be submitted for bacterial culture, but the results are typically difficult to interpret due to the normal flora found in the feline nasal cavity. In some areas, advanced imaging modalities are available, such as computed tomography (CT) that may prove useful for selected cases. Full evaluation for nasopharyngeal polyps will require sedation or anesthesia, and retraction of the soft palate.

Virus isolation can be used to document current infection but results are not available for several days and virus culture is not performed by all laboratories. PCR testing of oropharyngeal or conjunctival swabs for respiratory pathogens such as FHV-1 is widely available. Unfortunately, it appears that PCR assays are unable to distinguish between vaccine virus and natural infections.6 In addition, many respiratory pathogens can be detected in both symptomatic and clinically normal cats, making interpretation of a positive test result difficult. The negative predictive value of the FHV-1 PCR assays is also in question because many cats that are likely to have FHV-1 associated disease are PCR-negative. Treatment does not eliminate FHV-1 infection so there is no benefit to follow-up culture or PCR testing. Serological testing is not recommended; because of wide-spread exposure and vaccination, the PPV of serological tests is poor.

**The diagnostic plan**

Phase 1 (initial presentation): Thorough physical examination, good medical history, minimum database collection, therapeutic trials of antibiotics.
Phase 2 (when initial findings indicate further investigation or failure to respond to therapeutic trials):
Oropharyngeal exam under sedation, skull imaging (radiography, CT, MRI), rhinoscopy with collection of samples for histopathology and cultures, virus culture or PCR

**Treatment**

CRS is often resistant to therapy, and control of clinical signs, rather than cure, is the goal of therapy. Broad spectrum antibiotics (e.g., Clavamox, clindamycin, doxycycline or azithromycin) may be used to control secondary bacterial infections. If there is a positive response to antibiotic treatment, therapy should be continued for 6 weeks or longer, especially if osteomyelitis exists. Pulse therapy cannot be recommended due to the risk of developing resistant bacterial infections. However, many cats will relapse when therapy is discontinued. Some cats benefit from administration of antihistamines, especially if the symptoms are seasonal suggesting an allergic etiology. In cats with a history of infection with FHV-1, therapies may include lysine, antivirals and immunomodulators. One study found subjective improvement in clinical signs in response to cationic liposome DNA complexes (CLDC) immunomodulatory therapy. Further research is underway at Colorado State University. Another pilot study evaluated the effect of oral supplementation of Enterococcus faecium (FortiFlora®, Purina Veterinary Diets®) on a small number of cats with chronic FHV-1 infection. While the results were variable, the findings suggested that the probiotic lessened morbidity and that further studies are warranted.

Feline interferon omega (Virbagen® Omega, Virbac Animal Health) is often recommended for cats with acute and chronic upper respiratory tract disease, but results of controlled studies evaluating efficacy in clinically affected cats with respiratory disease are not available. Low dose oral human recombinant interferon therapy (30 U/kg, PO, daily alternating 7 days on, 7 days off) may be helpful through mediation of inflammatory cytokines. Controlled data on efficacy for treatment of FHV-1 and FCV are lacking. Topical administration of human recombinant interferon in saline to the eyes of cats with conjunctivitis or the nose has been recommended by some veterinarians as an aid in the management of some cats with acute or chronic FHV-1 or FCV infections, but again data on efficacy are lacking.

Antiviral drugs have become more popular in the management of cats with acute or chronic FHV-1 infections. Currently available antiviral medications are only efficacious for DNA viral infections such as FHV-1 and not RNA viruses like FCV as they interfere with viral DNA synthesis and thus viral replication. Famiclovir is safe and effective and is used for both acute and long-term therapy for cats with FHV-1 infections. One dose that has been used with apparent clinical efficacy is 62.5 mg, PO, BID for 14 days.13 However, recent pharmacokinetic studies indicate that higher doses may be needed for activity against FHV-1. Lysine at 250–500 mg, PO, BID may be helpful in some cats with acute or chronic rhinosinusitis from FHV-1 infection (not FCV). There is some evidence that lysine is not effective as a dietary supplement, and that bolus administration is more effective.

Intranasal administration of modified live FHV-1 and FCV vaccines may lessen disease in some chronically infected cats but controlled data are lacking. If there is a positive response, this form of immunotherapy can be administered up to three times per year.
Therapy with immunosuppressive medications, such as corticosteroids, should be used with caution as they may exacerbate viral and bacterial components of the disease. However, since CRS is likely multifactorial and is poorly understood, patients diagnosed with lymphocytic-plasmacytic rhinitis may respond to immunosuppressive drug therapy, such as prednisolone (1–2 mg/cat, PO, BID). The lowest dose and the longest dosing interval that is effective should be determined by adjusting the dose over time. Beclomethasone and fluticasone are available as inhaled formulations and may have direct beneficial effects on the nasal mucosa in some cases. They can be administered via metered dose inhaler with a feline inhalation chamber at 1–2 puffs once to twice daily. Finally, some cases will respond to cyclosporine (25 mg/cat, PO, once daily to once every other day). Trough blood levels should be checked two weeks after initiation of therapy to ensure that excessive blood levels are not achieved which may activate latent infectious diseases such as toxoplasmosis. Caution should be used in cats that are FeLV-or FIV-positive.

Nonspecific therapies include nebulization with saline and the use of saline nasal drops to help loosen secretions, especially in dry environments. Some veterinarians have mixed ophthalmic gentomycin with the saline and have had positive results. Some authorities recommend the use of pediatric nasal decongestant drops. The nares should be kept free of dried discharges. Olnappetent cats must be coaxed to eat or treated with appetite stimulants (e.g., cyproheptadine). In multi-cat environments, CRS can be a significant problem and measures to reduce environmental stressors may be beneficial. Feline facial pheromone (Feliway®, Ceva Animal Health) may also be helpful.